001461547 000__ 07488cam\a22006257a\4500
001461547 001__ 1461547
001461547 003__ OCoLC
001461547 005__ 20230503003358.0
001461547 006__ m\\\\\o\\d\\\\\\\\
001461547 007__ cr\un\nnnunnun
001461547 008__ 230318s2023\\\\sz\\\\\\o\\\\\001\0\eng\d
001461547 019__ $$a1373233442
001461547 020__ $$a9783031141003$$q(electronic bk.)
001461547 020__ $$a3031141008$$q(electronic bk.)
001461547 020__ $$z3031140990
001461547 020__ $$z9783031140990
001461547 0247_ $$a10.1007/978-3-031-14100-3$$2doi
001461547 035__ $$aSP(OCoLC)1373345361
001461547 040__ $$aEBLCP$$beng$$cEBLCP$$dGW5XE$$dEBLCP$$dYDX$$dOCLCF
001461547 049__ $$aISEA
001461547 050_4 $$aRS199.5
001461547 08204 $$a615/.6$$223/eng/20230324
001461547 24500 $$aTubercular drug delivery systems :$$badvances in treatment of infectious diseases /$$cRanjita Shegokar, Yashwant Pathak, editors.
001461547 260__ $$aCham :$$bSpringer,$$c2023.
001461547 300__ $$a1 online resource (334 p.)
001461547 500__ $$a3.2.5 Supercritical Fluid-Based Method
001461547 500__ $$aIncludes index.
001461547 5050_ $$aIntro -- Preface -- Volume 1: MDDS -- Volume 2: TDDS -- Volume 3: VDDS -- Volume 4: IDDS -- Contents -- Global Health and Tuberculosis -- Past, Present, and Future -- 1 What Is Tuberculosis -- 2 The History of the Outbreak -- 3 Treatments over the Time -- 4 Tuberculosis: World Scenario -- 4.1 Africa -- 4.2 Western Pacific/East Asia -- 4.3 Southern Asia -- 4.4 The Middle East -- 5 Conclusion and Future Trends -- References -- Tuberculosis: Cellular Understanding of Disease -- 1 Introduction -- 2 Mtb Complex -- 3 Initial Transmission of Mtb -- 4 Mechanism of Mtb-Host Interaction
001461547 5058_ $$a4.1 Phagocytosis and Immune Cells -- 4.2 Inhibition of Phagolysosome Maturation -- 4.3 Inhibition of Phagolysosome Acidification -- 4.4 Inhibition of Ubiquitination -- 5 Classification of Tuberculosis -- 5.1 Pulmonary and Extrapulmonary TB -- 5.1.1 Pulmonary TB -- 5.1.2 Extrapulmonary TB -- Miliary -- Spine (Pott's disease) -- Lymphatic (Tuberculous Lymphadenitis) -- 6 Organizations Involved in TB Research -- 7 Conclusion -- References -- Metal Nanoparticles in Tuberculosis -- 1 Introduction -- 2 Pathogenesis and Immunology of TB -- 3 Role of Macrophages
001461547 5058_ $$a3.1 Primary Phagosome-Lysosome Fusion Prevention -- 3.2 Escape of M.tb into the Cytosol -- 3.3 Non-phagocytic Internalization of M.tb in Macrophages -- 4 Interaction of Metal Nanoparticles and Macrophages -- 5 Diagnostic Applications -- 5.1 Noble Metal Nanoparticles and Metal Oxide Nanoparticles-Based Diagnostics -- 6 Metal Nanoparticles for Targeted Treatment -- 7 Toxicity Aspect of Metal Nanoparticles -- 8 Conclusion and Future Prospective -- References -- Tuberculosis: Current Treatment Options and Future Scope -- 1 Introduction -- 2 Current Treatment and Drug Regimen
001461547 5058_ $$a3 Challenges in Treatment of Tuberculosis -- 4 Recent Advancements in Treatment of Tuberculosis -- 4.1 Pharmaceutical Formulations -- 4.2 New Drugs or New Chemical Entities -- 4.3 Herbal Drugs -- 4.4 Recent Trials of New TB Drugs and Regimens -- 4.5 Vaccines -- 4.6 Others -- 5 Conclusions -- References -- Polymeric Nanoparticles in Tuberculosis -- 1 Introduction -- 2 Pathogenesis of Tuberculosis -- 3 Conventional Treatment and Its Limitation -- 4 Polymeric Nanoparticles -- 5 Polymer Used -- 5.1 Polysaccharide-Based Polymers -- 5.1.1 Chitosan Nanoparticles -- 5.1.2 Alginate Nanoparticles
001461547 5058_ $$a5.1.3 Guar Gum Nanoparticles -- 5.2 Polypeptide and Protein-Based Polymers -- 5.2.1 Gelatin-Based Polymers -- 5.2.2 Albumin-Based Polymers -- 5.3 Other Synthetic Polymers -- 5.3.1 PLGA Nanoparticles -- 6 Conclusion -- References -- Solid Lipid Nanoparticles in Tuberculosis -- 1 Introduction -- 2 Nanotechnology in TB -- 3 Solid Lipid Nanoparticle -- 3.1 Composition of SLN -- 3.2 Method of Preparation of SLN -- 3.2.1 High-Pressure Homogenization (HPH) -- 3.2.2 Phase Inversion Temperature (PIT) Method -- 3.2.3 Microemulsion Dilution -- 3.2.4 Coacervation Method
001461547 506__ $$aAccess limited to authorized users.
001461547 520__ $$aThe disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the microorganisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly persist as permanent and main threats to humanity now and in the future, primarily due to increased longevity that almost always comes at a cost of impaired immunity. A total of four books are covered under the series of Infectious diseases. Malarial drug delivery systems Tubercular drug delivery systems Viral drug delivery systems Infectious disease drug delivery systems The theme of the second book is Tuberculosis (TB). This book addresses the recent trends in drug delivery for treating TB using new formulation technologies, and the mechanism how it can prevent or delay the drug resistance. It covers current drug therapy and new drug targeting approaches focusing on innovative trend-defining technologies and drug delivery platforms. It is essential to understand the relationship between host pathogens for better treatment. Various novel and nano-formulations using promising technologies are being explored to deliver TB drugs via different administration routes at right pathological site. This book addresses the gap between new and old treatment TB modalities and how they are superior in pharmacological performance when tested in in-vitro and in-vivo. Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of TB research.
001461547 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed March 24, 2023).
001461547 650_0 $$aDrug delivery systems.
001461547 650_0 $$aCommunicable diseases$$xChemotherapy.
001461547 655_0 $$aElectronic books.
001461547 7001_ $$aShegokar, Ranjita.
001461547 7001_ $$aPathak, Yashwant.
001461547 77608 $$iPrint version:$$aShegokar, Ranjita$$tTubercular Drug Delivery Systems$$dCham : Springer International Publishing AG,c2023$$z9783031140990
001461547 852__ $$bebk
001461547 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-031-14100-3$$zOnline Access$$91397441.1
001461547 909CO $$ooai:library.usi.edu:1461547$$pGLOBAL_SET
001461547 980__ $$aBIB
001461547 980__ $$aEBOOK
001461547 982__ $$aEbook
001461547 983__ $$aOnline
001461547 994__ $$a92$$bISE